Schedule a Meeting
Download Brochure
Table of Content
February 2025
The global blood based biomarkers market size is calculated at USD 7.89 billion in 2024, grew to USD 8.46 billion in 2025, and is projected to reach around USD 15.78 billion by 2034. The market is expanding at a CAGR of 7.24% between 2025 and 2034. The growing research and development and advancements in diagnostics drive the market.
Unlock Infinite Advantages: Subscribe to Annual Membership
Blood-based biomarkers are indicators that can be measured using blood tests to detect the risk of developing a disease. A biomarker is a specific molecule, protein, or process that can be measured in the body and provide insights about a person’s health. These blood-based biomarkers can be measured using minimally invasive blood tests and are affordable, making them a valuable initial screening tool. They can detect numerous chronic disorders such as cancer, dementia, cardiovascular diseases, and renal disorders. Hence, blood-based biomarkers are vital for revealing underlying health issues, predicting future problems, and helping people to become more proactive with their health.
The rising incidences of chronic disorders necessitate detecting these disorders, boosting the market. Favorable government policies encourage early detection and screening of chronic disorders, promoting the detection of blood-based biomarkers. Advancements in diagnostics due to technological advancements also favor market growth. The growing research and development activities lead to continuous innovations in blood-based biomarker detection techniques.
Artificial intelligence (AI) and machine learning (ML) algorithms have disrupted the healthcare sector, providing numerous benefits. AI and ML can revolutionize blood-based biomarkers and help healthcare professionals analyze these biomarkers. This leads to effective disease diagnosis and prediction. AI and ML can also detect minute quantities of biomarkers present in blood that cannot be detected by traditional blood tests. They enhance the efficiency, accuracy, precision, and reproducibility of blood-based biomarker tests, reducing manual errors. They can also predict the future outcome of a chronic disorder through biomarker analysis. They offer cost-effective diagnostic tests and increase the accessibility of the test. Thus, AI and ML can introduce automation in blood test procedures, enabling quality control.
Favorable Government Support
The major growth factor in the blood based biomarkers market is favorable government support to promote early detection and screening of chronic disorders. Several government organizations and regulatory bodies have launched guidelines to create more awareness among the general public due to the rising incidences and prevalence of chronic disorders. The World Health Organization (WHO) recognizes non-communicable diseases as a global threat and released the “2030 Agenda for Sustainable Development”. The agenda aims to develop ambitious national responses by 2030 to reduce one-third of premature mortality from NCDs. The WHO also encourages several national and state governments to support its initiatives. Additionally, the rising adoption of smartphones and social media influences and educates people about the detection of chronic disorders. All these efforts facilitate blood tests and identify blood-based biomarkers.
Standardization
The major challenge faced by the market is the standardization issue of blood-based biomarker tests. They are difficult to measure and compare results between laboratories. It is also challenging to replicate results and detect minute quantities of biomarker levels. All these limitations restrict the market.
Personalized Treatments
The growing demand for personalized treatments presents the future blood based biomarkers market growth opportunities. Precision medicines are developed from a patient’s genetic profile to effectively treat a disease. The era of precision medicine demands more rigorous biomarker validation methods. The increasing investments and favorable government policies support the development of personalized treatments. Blood-based biomarkers are becoming essential in drug development and clinical practice. Additionally, regulatory agencies are adopting standards to support advanced techniques for disease identification. The identification of blood-based biomarkers enables researchers to develop personalized drugs based on these biomarkers. Apart from diagnosis, biomarkers are also used in disease prognosis and selection of targeted therapies, creating future opportunities for healthcare professionals.
By type, the genetic biomarkers segment held a dominant presence in the blood based biomarkers market in 2024. Some common examples of genetic blood-based biomarkers include cell-free DNA (cfDNA), circulating tumor DNA, (ctDNA), long non-coding RNA, circular RNA, and micro RNA (miRNA). These biomarkers are mainly used to detect the presence of tumors in blood, suggesting cancer risk. The rising incidences of cancer and advancements in liquid biopsy techniques potentiate the segment’s growth. The growing demand for personalized medicines also facilitates the demand for blood-based genetic biomarkers, allowing researchers to develop novel personalized therapeutics based on a person’s genetic information.
By type, the cell-based biomarkers segment is expected to grow at the fastest rate in the market during the forecast period. The growing genomics and proteomics research and the rising need for precision medicine boost the segment’s growth. Technological advancements in flow cytometry, cell sorter, cell analyzer, and immunocytochemistry drive the latest innovations in blood-based biomarkers. Cell-based biomarkers are measured in blood or any body fluid, allowing for isolation, sorting, quantification, and characterization of cells by their morphology and physiology properties.
By application, the cancer segment held the largest share of the blood based biomarkers market in 2024. The segment's growth is aided by increasing research and development efforts as well as rising cancer incidence and prevalence. Numerous researchers are examining the possibility of new blood-based biomarkers in the course of cancer. The need for blood-based biomarker diagnostic testing is increased by the increased knowledge of liquid biopsy procedures. The prognosis of cancer is influenced by a variety of biomarkers, including cellular, protein, and genetic ones.
By application, the neurological diseases segment is anticipated to grow with the highest CAGR in the market during the studied years. The use of blood-based biomarker tests is required due to the increasing incidence and prevalence of neurological illnesses including Parkinson's and Alzheimer's. The discovery of new biomarkers is encouraged by the expansion of research and development initiatives as well as rising financial investments. The most often evaluated biomarkers are phosphorylated tau (p-tau) and Aβ42 to Aβ40.
By technology, the next-generation sequencing segment led the global blood based biomarkers market in 2024. Next-generation sequencing (NGS) is an advanced DNA-sequencing technology used for parallel sequencing of multiple small fragments of DNA and detecting mutation. It is widely preferred as it offers ultra-high throughput, scalability, and speed. Technological advancements such as AI and ML introduce automation and enhance its accuracy and precision. NGS-based biomarker tests can analyze hundreds of cancer biomarkers simultaneously.
By technology, the polymerase chain reaction segment is predicted to witness significant growth in the market over the forecast period. Polymerase chain reaction (PCR) is a technology to amplify multiple copies of DNA segments. The advent of RT-PCR (Reverse Transcriptase) technology favors the segment’s growth. RT-PCR provides fast, reliable, and precise results, enhancing affordability and accessibility. The growing demand for companion diagnostics also promotes the use of PCR in blood-based biomarker tests.
By end-use, the hospitals & clinics segment registered its dominance over the global blood based biomarkers market in 2024. The segmental growth is attributed to suitable infrastructure and the presence of trained professionals. Hospitals have experts from multidisciplinary domains, providing multidisciplinary expertise. The availability of suitable capital investments enables healthcare professionals to adopt advanced technologies. The increasing number of patients in hospitals and clinics for primary care encourages the use of blood-based biomarker tests. Hospitals and clinics conduct several clinical trials, enabling patients to have access to advanced techniques before market approval.
By end-use, the diagnostic laboratories segment will gain a significant share of the market over the studied period. The availability of specialized equipment and the presence of skilled professionals fuel the segment’s growth. They provide advanced services such as withdrawing blood from a patient’s home and providing results online, eliminating the need for patients to visit the laboratory. They offer special discounts and offers to attract more customers, strengthening their market position.
North America dominated the global blood based biomarkers market in 2024. Technological advancements and favorable government policies drive the market. The U.S. and Canadian government supports research related to the discovery of novel biomarkers and provide funding for conducting such research. Several government bodies also encourage people for early detection and screening of chronic disorders. The presence of key players also holds a major share of the market. Additionally, the increasing investments and collaborations also contribute to market growth. The rising incidences of chronic disorders such as Alzheimer’s disease and cancer potentiate the demand for blood-based biomarkers. As of January 2025, approximately 0.77 million people in Canada were living with dementia. Moreover, the state-of-the-art research and development facilities favor the development of blood-based biomarker tests.
Asia-Pacific is projected to host the fastest-growing blood based biomarkers market in the coming years. The rising incidences of chronic disorders and growing research and development activities drive the market. Favorable government policies and increasing investments contribute to the market. The rising collaborations and mergers & acquisitions enable key players to utilize advanced technology and expertise to identify novel blood-based biomarkers. The burgeoning pharmaceutical and biotechnology fields and the growing demand for precision medicine propel the market. The Chinese government launched the “Chinese Personal Medicine Initiative” with a funding of $9 billion by 2030. Additionally, the growing awareness for early detection of chronic disorders and increasing regular blood tests fuel the market. The rising healthcare expenditure is also one of the major growth factors of the market in Asia-Pacific.
Jane Grogan, Head of Research at Biogen, commented on collaboration with Beckman Coulter and Fujirebio that the company aims to leverage deep scientific expertise in the development and use of biomarkers combined with the partners’ capabilities in diagnostics, accelerating the development timeline for blood-based diagnostics to measure a patient’s levels of tau pathology.
By Type
By Application
By Technology
By End-Use
By Region
February 2025
December 2024
November 2024
November 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts